Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparative effects of fixed-dose mitiglinide/voglibose combination and glimepiride on vascular endothelial function and glycemic variability in patients with type 2 diabetes: A randomized controlled trial.
Tanaka K, Okada Y, Umezu S, Hashimoto R, Tomoyose Y, Tateyama R, Hori Y, Saito M, Tokutsu A, Sonoda S, Uemura F, Kurozumi A, Tanaka Y. Tanaka K, et al. Among authors: uemura f. J Diabetes Investig. 2024 Apr;15(4):449-458. doi: 10.1111/jdi.14138. Epub 2023 Dec 27. J Diabetes Investig. 2024. PMID: 38149694 Free PMC article. Clinical Trial.
Blood pressure reduction with empagliflozin in Japanese patients with type 2 diabetes and cardiovascular diseases: a post-hoc sub-analysis of the placebo-controlled randomized EMBLEM trial.
Tanaka A, Shimabukuro M, Teragawa H, Yoshida H, Okada Y, Takamura T, Taguchi I, Toyoda S, Tomiyama H, Ueda S, Higashi Y, Node K; EMBLEM Investigators. Tanaka A, et al. Hypertens Res. 2024 Sep;47(9):2295-2302. doi: 10.1038/s41440-024-01725-4. Epub 2024 May 24. Hypertens Res. 2024. PMID: 38789538 Clinical Trial.
Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial.
Tanaka A, Sata M, Okada Y, Teragawa H, Eguchi K, Shimabukuro M, Taguchi I, Matsunaga K, Kanzaki Y, Yoshida H, Ishizu T, Ueda S, Kitakaze M, Murohara T, Node K; PROTECT study investigators. Tanaka A, et al. Eur Heart J Cardiovasc Pharmacother. 2023 Feb 2;9(2):165-172. doi: 10.1093/ehjcvp/pvac059. Eur Heart J Cardiovasc Pharmacother. 2023. PMID: 36308299 Free PMC article. Clinical Trial.
Risk Factor Analysis for Type 2 Diabetes Patients About Hypoglycemia Using Continuous Glucose Monitoring: Results from a Prospective Observational Study.
Uemura F, Okada Y, Mita T, Torimoto K, Wakasugi S, Katakami N, Yoshii H, Matsushita K, Nishida K, Inokuchi N, Tanaka Y, Gosho M, Shimomura I, Watada H. Uemura F, et al. Diabetes Technol Ther. 2022 Jun;24(6):435-445. doi: 10.1089/dia.2021.0465. Epub 2022 Feb 15. Diabetes Technol Ther. 2022. PMID: 35049378
39 results